Table 3.

Recommendation for HBV treatment based on non-invasive tests results regardless of HBV-DNA and/or ALT levels.

	WHO 2024	ALEH 2011	PAHO 2015	AALSD 2018	Brazil 2023	Uruguay 2022	Argentina 2021	Chile 2021	Mexico 2021	Peru 2018	Colombia 2016
Use of NITs for treatment indication in people with HBV	Yes APRI >0.5 or TE-Fibroscan >7 kPa	Not described	Yes APRI >2 TE-Fibroscan Cut-off?	Yes TE-Fibroscan, FibroTest or FIB-4 ≥ F2	Yes Liver elastography (Fibroscan, p-SWE or 2D-SWE) TE-Fibroscan >9 kPa if normal ALT or > 12 kPa if elevated ALT; p-SWE >1.8 m/s; 2D-SWE >10 kPa	Not described	Not described	No TE-Fibroscan only if HBV-DNA≥ 2000 UI/ml	Yes FIB-4, FibroTest or TE-Fibroscan	Yes APRI >2 or TE-Fibroscan >12 kPa	Yes APRI >2

AASLD, American Association for the Study of Liver Diseases; ALEH, Asociación Latinoamericana para el Estudio del Hígado; APRI, aspartate-to-platelet ratio index; FIB-4, fibrosis-4 score; NIT, non-invasive test; PAHO, Pan American Health Organization; SWE, shear-wave elastography; TE, transient elastography; WHO, World Health Organization. For links to guidelines see Supplementary Table S1.